Spots Global Cancer Trial Database for Fruquintinib Combined With Sintilimab as Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Fruquintinib Combined With Sintilimab as Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma

Official Title: A Single-center, Single-arm, Open-label, Exploratory Study Evaluating Fruquintinib Combined With Sintilimab in Second-line Treatment of Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma

Study ID: NCT05625737

Conditions

Stomach Neoplasms

Interventions

Fruquintinib

Sintilimab

Study Description

Brief Summary: This was a single-arm, prospective study to investigate the efficacy and safety of fruquintinib combined with sintilimab in the second-line treatment of Chinese patients with advanced gastric/GEJ adenocarcinoma.

Detailed Description: Patients with adenocarcinoma of the gastro-esophageal junction or the stomach who have documented progression after being treated with a 1st line chemotherapy can be included. All patients will receive a second line therapy with fruquintinib and sintilimab, a checkpoint inhibitor. Clinical and radiographic assessment will be performed regularly. Patients will be treated until disease progression, untolerable toxicity or withdrawal of consent.